1. Home
  2. SILO vs GXAI Comparison

SILO vs GXAI Comparison

Compare SILO & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SILO
  • GXAI
  • Stock Information
  • Founded
  • SILO 2010
  • GXAI 2021
  • Country
  • SILO United States
  • GXAI United States
  • Employees
  • SILO N/A
  • GXAI N/A
  • Industry
  • SILO Apparel
  • GXAI
  • Sector
  • SILO Consumer Discretionary
  • GXAI
  • Exchange
  • SILO Nasdaq
  • GXAI Nasdaq
  • Market Cap
  • SILO 8.8M
  • GXAI 7.5M
  • IPO Year
  • SILO N/A
  • GXAI 2023
  • Fundamental
  • Price
  • SILO $1.65
  • GXAI $1.53
  • Analyst Decision
  • SILO
  • GXAI
  • Analyst Count
  • SILO 0
  • GXAI 0
  • Target Price
  • SILO N/A
  • GXAI N/A
  • AVG Volume (30 Days)
  • SILO 805.4K
  • GXAI 707.0K
  • Earning Date
  • SILO 02-18-2025
  • GXAI 03-26-2025
  • Dividend Yield
  • SILO N/A
  • GXAI N/A
  • EPS Growth
  • SILO N/A
  • GXAI N/A
  • EPS
  • SILO N/A
  • GXAI N/A
  • Revenue
  • SILO $72,102.00
  • GXAI $2,979.00
  • Revenue This Year
  • SILO $1.86
  • GXAI N/A
  • Revenue Next Year
  • SILO N/A
  • GXAI N/A
  • P/E Ratio
  • SILO N/A
  • GXAI N/A
  • Revenue Growth
  • SILO N/A
  • GXAI N/A
  • 52 Week Low
  • SILO $0.77
  • GXAI $1.01
  • 52 Week High
  • SILO $4.50
  • GXAI $19.20
  • Technical
  • Relative Strength Index (RSI)
  • SILO 52.57
  • GXAI 40.09
  • Support Level
  • SILO $1.56
  • GXAI $1.35
  • Resistance Level
  • SILO $1.89
  • GXAI $2.22
  • Average True Range (ATR)
  • SILO 0.19
  • GXAI 0.15
  • MACD
  • SILO -0.05
  • GXAI -0.03
  • Stochastic Oscillator
  • SILO 27.12
  • GXAI 19.54

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

About GXAI Gaxos.ai Inc.

Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.

Share on Social Networks: